drugset
drugset / Trial / NCT03732846

Anlotinib in Treatment of Recurrent Small Cell Lung Cancer

NCT03732846 ↗

Phase 2 Unknown 43 enrolled Peking University Cancer Hospital & Institute
NaSingle-groupOpen-labelTreatment

Summary

Exploring the efficacy and safety of Anlotinib in patients with relapsed small cell lung cancer

Timeline

Start
2018-11-01
Primary completion
2020-05-01
Completion
2020-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 12 mg —

Indications

small cell lung carcinoma